Placebo News and Research

RSS

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

Cancer researchers are constantly in search of more-effective and less-toxic approaches to stopping the disease, and have recently launched clinical trials testing a new class of drugs called BET inhibitors. These therapies act on a group of proteins that help regulate the expression of many genes, some of which play a role in cancer.

25 Aug 2015

Repetitive sacral root magnetic stimulation can reduce frequency of nighttime bedwetting

Bedwetting, or nocturnal enuresis, causes distress in children and young adults, as well as for their parents or caregivers. The causes are not fully understood and there may be both physiological and psychological components to the condition. In a new study published in Restorative Neurology and Neuroscience, researchers report that repetitive sacral root magnetic stimulation (rSMS) can reduce the frequency of nighttime bedwetting and improve quality-of-life for sufferers.

24 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

Researchers find effectiveness of ramelteon for treatment of sleep disturbances after TBI

Kessler researchers found preliminary evidence for the effectiveness of ramelteon for the treatment of sleep disturbances after traumatic brain injury (TBI). The article, "Archives of Physical Medicine and Rehabilitation on May 28, 2015. Authors are Anthony Lequerica, PhD, and Nancy Chiaravalloti, PhD, of Kessler Foundation, Neil Jasey, MD, of Kessler Institute for Rehabilitation, and Jaclyn Portelli Tremont, MA, of Robert Wood Johnson Medical School, Rutgers University.

21 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

IQWiG finds no added benefit for safinamide in Parkinson disease

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.

20 Aug 2015

Common diabetes drug metformin works in gut, not the bloodstream

Although metformin was introduced as a treatment for type 2 diabetes nearly 60 years ago and is now the recommended first-line treatment for newly diagnosed patients, researchers still debate precisely how the drug works.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Study shows alcohol intoxication does not affect accuracy of sexual assault testimonies

People are often concerned about the accuracy of testimony given by victims who were intoxicated during a sexual assault- but a new study by University of Leicester researchers has found that while alcohol intoxicated participants report fewer pieces of information about an assault, the information that they do provide is just as accurate as sober participants.

19 Aug 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

Intoxicated victims of sexual violence could accurately retain information from events

18 Aug 2015

Researchers examine how GABA supplementation enhances planning, controls different actions

People show an enhanced ability of prioritizing planned actions after the ingestion of the food supplement GABA. Psychologists Laura Steenbergen and Lorenza Colzato, with their colleagues at the Leiden Institute of Brain and Cognition and fellow researchers from the Technical University of Dresden, published their findings in Scientific Reports.

18 Aug 2015

Vitamin D supplements may help reduce risk of falls in homebound elderly

Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury. Even if an injury does not occur, the fear of falling can lead to reduced activity and a loss of independence.

18 Aug 2015

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Boehringer Ingelheim announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD

17 Aug 2015

Omeros plans to file patent infringement lawsuit against Par

Omeros Corporation today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

17 Aug 2015

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.

13 Aug 2015

Placebo News and Research

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

Repetitive sacral root magnetic stimulation can reduce frequency of nighttime bedwetting

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

Researchers find effectiveness of ramelteon for treatment of sleep disturbances after TBI

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

IQWiG finds no added benefit for safinamide in Parkinson disease

Common diabetes drug metformin works in gut, not the bloodstream

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Study shows alcohol intoxication does not affect accuracy of sexual assault testimonies

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Intoxicated victims of sexual violence could accurately retain information from events

Researchers examine how GABA supplementation enhances planning, controls different actions

Vitamin D supplements may help reduce risk of falls in homebound elderly

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Omeros plans to file patent infringement lawsuit against Par

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News